Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Prevail Therapeutics Inc (PRVL)

Prevail Therapeutics Inc (PRVL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 787,658
  • Shares Outstanding, K 34,246
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,190 K
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.99
Trade PRVL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.77
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/17/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.64
  • Number of Estimates 8
  • High Estimate -0.61
  • Low Estimate -0.68
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -20.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.80 +0.88%
on 01/04/21
23.30 -1.29%
on 01/13/21
-0.09 (-0.39%)
since 12/21/20
3-Month
9.21 +149.73%
on 10/30/20
23.35 -1.50%
on 12/17/20
+13.00 (+130.00%)
since 10/21/20
52-Week
9.02 +154.99%
on 03/12/20
23.35 -1.50%
on 12/17/20
+4.71 (+25.75%)
since 01/21/20

Most Recent Stories

More News
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates BPFH, SPWH, PRVL, SNCA; Shareholders Are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / January 13, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Boston Private Financial Holdings, Inc. (NASDAQ:BPFH)...

BPFH : 14.75 (+0.07%)
SPWH : 9.59 (-1.84%)
PRVL : 23.00 (-0.09%)
SNCA : 9.9600 (-1.19%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates BPFH, MDCA, MTSC, PRVL; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

BPFH : 14.75 (+0.07%)
MDCA : 5.42 (-3.39%)
MTSC : 58.49 (-0.02%)
PRVL : 23.00 (-0.09%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLNX, ANH, TCF, PRVL; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

XLNX : 194.92 (-9.99%)
ANH : 2.98 (+0.34%)
TCF : 45.18 (-3.28%)
PRVL : 23.00 (-0.09%)
(PRVL Alert) Johnson Fistel Investigates Proposed Sale of Prevail; Are Shareholders Getting a Fair Deal?

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Prevail Therapeutics Inc. ("Prevail" or the...

PRVL : 23.00 (-0.09%)
LLY : 323.48 (+3.20%)
Lifshitz Law Firm, P.C. Announces Investigation of INFO, LORL, PS, and PRVL

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Lifshitz Law Firm, P.C.: IHS Markit Ltd. (NYSE:INFO) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection...

INFO : 108.61 (+0.74%)
LORL : 41.52 (-7.20%)
PS : 22.45 (+0.13%)
PRVL : 23.00 (-0.09%)
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies – MTSC, PRVL, ANH, CPAH

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

MTSC : 58.49 (-0.02%)
PRVL : 23.00 (-0.09%)
ANH : 2.98 (+0.34%)
CPAH : 3.48 (+0.43%)
Halper Sadeh LLP Investigates the Following Mergers; Shareholders are Encouraged to Contact the Firm – CATM, PRVL, TCP, TLRY

NEW YORK, NY / ACCESSWIRE / December 23, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cardtronics plc (NASDAQ:CATM) concerning potential...

CATM : 39.01 (+0.08%)
PRVL : 23.00 (-0.09%)
TCP : 30.21 (+1.65%)
TLRY : 4.55 (-2.36%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – ANH, TCF, PRVL, ZAGG

NEW YORK, Dec. 19, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

ANH : 2.98 (+0.34%)
TCF : 45.18 (-3.28%)
PRVL : 23.00 (-0.09%)
ZAGG : 4.29 (+0.70%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout

WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL ) regarding possible breaches...

PRVL : 23.00 (-0.09%)
LLY : 323.48 (+3.20%)
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Prevail Therapeutics,...

PRVL : 23.00 (-0.09%)
LLY : 323.48 (+3.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Prevail Therapeutics Inc. is a gene therapy company. It focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's product candidate consists of PR001, PR006 and PR004 which are in clinical stage. Prevail...

See More

Key Turning Points

3rd Resistance Point 23.26
2nd Resistance Point 23.19
1st Resistance Point 23.10
Last Price 23.00
1st Support Level 22.94
2nd Support Level 22.87
3rd Support Level 22.78

See More

52-Week High 23.35
Last Price 23.00
Fibonacci 61.8% 17.88
Fibonacci 50% 16.19
Fibonacci 38.2% 14.49
52-Week Low 9.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar